Kornimate/medical-research-clean huggingface dataset:
pten and igfbp-3 correlation in ovarian carcinoma invasion

Conditions: Ovarian Cancer

Summary: we have identified insulin-like growth factor binding protein (igfbp)-3 as an invasion suppressor gene in ovarian endometrioid carcinoma, and showed association with lower cancer migration, invasion and metastasis. recently, a novel model of ovarian ec formation from endometriosis was reported, and pten was found to be a major protein involved. inactivation of pten has been reported in some ovarian ec tumors and methylation was suggested as one of the major epigenetic changes. this tumorigenesis model has lots of similarity to our established invasion model. therefore, we plan to study the important of pten expression in ovarian ec and if inactivation of pten and ifgbp-3 is through methylation. furthermore, by studying the signal transduction pathways using pten and igfbp-3 transfection, we plan to study the mutual interaction between pten and igfbp-3 on the suppression of tumor invasion in ovarian ec.

we have successfully established an ovarian cancer cell line (ovtw-59), which was derived from an ovarian endometrioid carcinoma (ec), and have also established an ovarian ec invasion model. by using cdna microarray and quantitative reverse-transcriptase polymerase chain reaction, we identified insulin-like growth factor binding protein (igfbp)-3 as an invasion suppressor gene, which were associated with lower cancer migration, invasion and metastasis. clinically, lower igfbp-3 was found associated with significantly higher tumor grade, advanced stage and poor survival in patients with ec tumors. furthermore, we have proved igfbp-3 expression correlated with lower erk activation, but with no effect on the activation of akt. all these two signal transduction proteins have crucial roles in cancer invasion. recently, a novel model of ovarian ec formation from endometriosis was reported, and pten was found to be a major protein involved. inactivation of pten has been reported in some ovarian ec tumors and methylation was suggested as one of the major epigenetic changes. this tumorigenesis model has lots of similarity to our established invasion model. therefore, we plan to study the important of pten expression in ovarian ec and if inactivation of pten and ifgbp-3 is through methylation. furthermore, by studying the signal transduction pathways using pten and igfbp-3 transfection, we plan to study the mutual interaction between pten and igfbp-3 on the suppression of tumor invasion in ovarian ec.

Eligibility criteria:
inclusion criteria: clinical diagnosis of ovarian endometrioid carcinoma exclusion criteria: other types of ovarian epithelial carcinoma

Keywords: ovarian endometrioid carcinoma invasion igfbp-3 transfection signal transduction pten methylation
retrospective study evaluating igf1r and p95her2 as prognostic factors in non small cell lung cancer (nsclc)

Conditions: Non Small Cell Lung Cancer

Summary: aim of the study is to evaluated the role of igf1r and p95her2 on prognosis in radically resected non small cell lung cancer patients the primary objective is to correlate the expression of igf1r and p95her2 with survival.


Eligibility criteria:
inclusion criteria: * radically resected non small cell lung cancer patients with tumor tissue available exclusion criteria: * tumor tissue not available * clinical data not available

Keywords: non small cell lung cancer patients
a retrospective observational study on the use of biologics in monotherapy in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this retrospective, observational, multi-center study will evaluate the use of biological agents (e.g. roactemra/actemra \[tocilizumab\]) in monotherapy in patients with rheumatoid arthritis. data from medical record files will be collected of patients currently treated with a biologic in monotherapy.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * diagnosis of rheumatoid arthritis * currently receiving a biologic agent in monotherapy (corticosteroids and/or non-steroidal anti-inflammatory drugs are permitted) exclusion criteria: * concomitant treatment with disease-modifying anti-rheumatic drugs (dmards) for the treatment of rheumatoid arthritis * patients that have started their current monotherapy before 01/01/2009
dna analysis of tumor tissue samples from young patients with acute lymphoblastic leukemia

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission; Recurrent Childhood Acute Lymphoblastic Leukemia

Summary: this laboratory study is looking at dna in tumor tissue samples from young patients with acute lymphoblastic leukemia. dna analysis of tumor tissue may help doctors predict how well patients will respond to treatment

primary objective: i. to validate significant associations between snps and treatment outcome and toxicity on children's cancer group (ccg)-1891 on an independent sample set from a successor ccg study for standard risk acute lymphoblastic leukemia (all), ccg-1952. ii. to evaluate the role of snps in drug metabolizing enzymes and the development of veno-occlusive disease in patients on ccg-1952. iii. to evaluate interactions among genotypes and other risk factors for treatment response in a combined data set of ccg-1891 and ccg-1952 with recently developed analytic tools for high dimensional data. iv. to develop predictive models utilizing genetic information obtained in aim 1.1 and clinical data to predict treatment response and toxicity. outline: tumor tissue samples undergo genotype assessment on the pyrosequencing platform. contingency tables and x\^2 test performs a univariate analysis of the risk of relapse and genotype, and multivariable analyses using logistic regression. cox proportional hazards evaluate the risk of relapse given genotype and other confounders. genotype patterning, classification and regression trees, and multifactor dimensionality reduction evaluates for patterns of single nucleotide polymorphisms associated with toxicity and relapse risk.

Eligibility criteria:
inclusion criteria: * enrolled in clinical trial ccg-1891 or ccg-1952 with pediatric all
molecular imaging of dna damage response by [18f]-olaparib pet

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)

Summary: this is a single-centre, non-randomized, two-stage design, proof-of-concept study evaluating the radiolabelled parp inhibitor \[18f\]-olaparib als potential tracer for imaging of tumour parp expression by pet.


Eligibility criteria:
inclusion criteria: 1. patients \>18y, with biopsy-proven hpv-negative hnscc, or patients \>40y with hpv-positive hnscc and high-risk features (i.e. \> 10 smoke packs/year and ≥n2b) 2. treatment with chemoradiotherapy using platinum-based chemotherapy is anticipated 3. recent archival tumour tissue (\<8 weeks prior to inclusion) should be available with suffi-cient residual material for determination of tumour parp1 levels 4. presence of a tumour lesion ≥10 mm in diameter 5. ecog performance status 0-2 6. negative pregnancy test in women with childbearing potential 7. life expectancy \>3 months 8. signed written informed consent and able to comply with the protocol 9. for stage ii only: re-biopsy should be deemed feasible by the investigators (assessed by head-and-neck surgeon) exclusion criteria: 1. recent treatment with parp inhibitors or other investigational therapies \<30 days. 2. presence of significant co-morbidities that make participation in the study undesirable according to the treating physician.
effects of agility training with and without foot mobilization in patellofemoral pain syndrome.

Conditions: Patellofemoral Pain Syndrome

Summary: patellofemoral pain syndrome (pfps) is referred to as peripatellar or retro-patellar pain, which is characterized by alterations in the physical and biomechanical features of the patellofemoral joint. risk factors for pfps include: anatomic anomalies, mal-alignment and altered biomechanics of the lower extremity, muscle dysfunction, patellar hypermobility, poor quadriceps, or iliotibial band flexibility, surgery, tight lateral structures, training errors or overuse and trauma. the aim of this study is to compare the effects of foot mobilization with and without agility training on pain, balance and functional performance in patellofemoral pain syndrome.

a randomized clinical trial will be conducted at riphah clinic lahore, al rehman hospital, through convenient purposive sampling technique on 42 patients which will be allocated through using simple randomization into group a and group b. group a will be treated with agility training and foot mobilization in patellofemoral pain syndrome and group b will be treated with agility training without foot mobilization in patellofemoral pain syndrome thrice a week for 6 weeks. outcome measures will be conducted through pain (nprs), kujala patellofemoral pain scale, y balance test and navicular droop test before and after 6 weeks. data will be analyzed using spss software version 25.

Eligibility criteria:
inclusion criteria: clinical signs of patellofemoral pain syndrome such as retro patellar pain, crepitation, and pain with patellar grinding more than 6 months. * both genders of 20-40 years of age. * presence of pain on step down from a 25 step or double leg squat and sitting with knee bent greater than 15 min. * pain more than 4 on nprs scale. * individual with anterior left/right asymmetries greater than 4 cm on y balance test * excessive calcaneal eversion measured at 6° in the relaxed posture(6). exclusion criteria: * history of ligament and meniscal injury. * history of lower limb fractures. * history of post-surgical condition of lower limb * history of systemic, connective tissue or neurologic condition

Keywords: balance functional performance flat foot kujala function scale patellofemoral pain syndrome pain
metabolism, exercise and nutrition at ucsd (menu study)

Conditions: Obese; Nondiabetic

Summary: the purpose of the menu study is to examine whether there is a differential weight loss response to different dietary macronutrient composition (higher carbohydrate and lower fat versus lower carbohydrate and higher monounsaturated fat \[mufa\] or lower carbohydrate and walnut-rich higher fat diets) in a weight loss intervention in healthy obese women, depending on insulin resistance status. blood samples will be collected to enable analysis of potential mechanisms and differential response across subgroups.


Eligibility criteria:
inclusion criteria: * aged 21 years and older * have bmi \>30.0 kg/m2 and \<40 kg/m2 * willing and able to participate in clinic visits, group sessions, and telephone and internet communications at specified intervals * able to provide data through questionnaires and by telephone * willing to maintain contact with the investigators for 12 months * willing to allow blood collections * no known allergy to tree nuts * able to be physically active exclusion criteria: * diabetic * inability to be moderately physically active * a history or presence of a comorbid diseases for which diet modification and increased physical activity may be contraindicated * currently pregnant/breastfeeding * planning to become pregnant within the next year * currently enrolled in a weight loss program or diet intervention study * current use of weight loss medication or supplements * planned surgical procedure that can impact the conduct of the study * have plans to relocate from area within the next year * 6+ months use of meds likely to cause weight gain or prevent weight loss * any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in this study

Keywords: obese women weight loss exercise physical activity diet female
association between body composition and pain in spinal cord injury

Conditions: Pain; Inflammatory Response

Summary: the purposes of the study are to quantify and compare relationships among acute changes in inflammatory markers and evoked pain sensitivity after a high-fat meal (hfm) challenge, compared to a moderate-fat meal challenge, and explore the influence of body composition on these responses, in individuals with chronic spinal cord injury


Eligibility criteria:
inclusion criteria: * age 18-65 years * sci occurring at least 2 years prior to study entry * neurological level of injury (loi) between c4 and l2 * american spinal injury association impairment scale (ais) a-d * english-speaking. exclusion criteria: * cognitive dysfunction that limits ability to adequately understand the risks of the study or are otherwise unable to consent * health conditions associated with chronic systemic inflammation unrelated to weight or adiposity (e.g., systemic autoimmune diseases, recurrent or active urinary tract infection, pressure injury \> stage 2) * conditions that preclude measurement of body composition by dual-energy x-ray absorptiometry (dxa; e.g., lower limb contracture \> 15 degrees) * inability to obtain free-flowing blood from a superficial forearm or hand vein * pregnant women * prisoners
investigation of single ascending doses of nnc9204-1706 in male subjects being overweight or with obesity

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this trial is conducted in the united states of america (usa). the aim of this trial is to assess the safety and tolerability of single doses of nnc9204-1706 administered subcutaneously in male subjects being overweight or with obesity.


Eligibility criteria:
inclusion criteria: * male subjects aged 18-55 years (both inclusive) at the time of signing informed consent * body mass index (bmi) between 25.0 and 34.9 kg/m\^2 (both inclusive) at screening. overweight should be due to excess of adipose tissue, as judged by the investigator exclusion criteria: * any disorder which in the investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol * subjects, aged at least 40 years, with an estimated 10-year atherosclerotic cardiovascular disease (ascvd) (as described in the american college of cardiology and the american heart association prevention guideline) risk equal to or above 5% * male subjects who are not sexually abstinent or surgically sterilised (vasectomy) and are sexually active with female partner(s) and who are not using a highly effective method of contraception (such as condom with spermicide) combined with a highly effective method of contraception for their non-pregnant female partner(s) (pearl index below 1%, such as implants, injectables, oral contraceptives, intrauterine devices, diaphragm or cervical cap+spermicide), and/or intend to donate sperm in the period from screening until 3 months following administration of the investigational medical product
efficacy and safety study of aprepitant injection for prevention of post-operative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting

Summary: the goal of this interventional study is to evaluate the efficacy and safety of aprepitant injection(qlg2174) for preventing ponv in chinese patients.


Eligibility criteria:
inclusion criteria: * aged 18 to 70 years, with a body mass index (bmi) of 18-30 kg/m² and body weight≥45kg. * laparoscopic gynecologic or abdominal surgery under general anesthesia (duration≥1 hour and postoperative hospitalization ≥24 hours), with anesthesia maintained using sevoflurane and remifentanil (propofol maintenance was prohibited); * had≥2 risk factors of ponv; expected to use postoperative opioid within 24 hours after surgery; * american society of anesthesiologists (asa) physical status class i-iii. exclusion criteria: * planned intrathoracic, transplant, or central nervous system surgeries; * diagnostic-only procedures; * use of local/regional anesthesia (e.g., neuraxial/nerve blocks); * postoperative intensive care unit (icu) transfer; * preoperative nasogastric/orogastric tube placement (from screening through 24 hours postoperatively) * nausea, vomiting, retching, or organic disease-related emesis (e.g., intestinal obstruction) within 24 hours preoperatively; history of malignancy, epilepsy, or vestibular dysfunction; * hypersensitivity to aprepitant; * recent use of aprepitant/nk1 antagonists (within 2 weeks prior to randomization), antiemetics (including 5-ht3 antagonists, corticosteroids; within 1 week), strong cyp3a4 inhibitors/substrates (within 1 week), cyp3a4 inducers (within 4 weeks), or warfarin (within 2 weeks); * clinically significant laboratory abnormalities (alt/ast ≥2×upper limit of normal \[uln\], total bilirubin ≥1.5×uln, creatinine ≥1.5×uln, hemoglobin ≤90 g/l)
early primary prophylaxis of esophageal varices

Conditions: Cirrhosis

Summary: patients of cirrhosis with portal hypertension aged 18 to 75 years who have small esophageal varices with or without red color signs and have not bled previously will be enrolled. after baseline evaluation, the participants will be randomized to receive either placebo or carvedilol 12.5 mg bd. after randomization they will be followed up for one year. the primary endpoint of the study is the the proportions of patients who develop large varices (gd 3 or gd 4) at 1 year in each group. the secondary endpoint are survival,reduction in hvpg,change in ctp and meld score\& adverse events.


Eligibility criteria:
inclusion criteria: - patients of cirrhosis with portal hypertension aged 18 to 75 years who have small esophageal varices with or without red color signs and have not bled previously. exclusion criteria: * any contra-indication to beta-blockers * any evl or sclerotherapy within last 3 months * child turcotte pugh (ctp) score \> 12, refractory ascites, hepatorenal syndrome * any past history of surgery for portal hypertension * significant cardio or pulmonary co-morbidity * any malignancy that affects survival. * active alcohol abuse or last intake ≤ 4 weeks to avoid possibility of ongoing alcohol hepatitis. * past history of surgery for portal hypertension * uncontrolled diabetes * peripheral vascular disease * refusal to participate in the study
treatment of patients with major depressive disorder with mk0869 (0869-062)(completed)

Conditions: Major Depressive Disorder

Summary: a clinical study to determine the efficacy and safety of mk0869 in the treatment of depression

the duration of treatment is 8 weeks.

Eligibility criteria:
patients with major depressive disorder
evaluation of n-sweat patch for treatment of primary axillary hyperhidrosis or excessive axillary sweating

Conditions: Primary Axillary Hyperhidrosis

Summary: the sahara study is a study to evaluate the safety and effectiveness of the n-sweat patch for use in subjects with excessive axillary sweating, or primary focal axillary hyperhidrosis.

the sahara study is intended to evaluate the safety and effectiveness of the n-sweat patch for use in subjects with excessive axillary sweating, or primary focal axillary hyperhidrosis. safety of the n-sweat patch will be confirmed by assessing the occurrence of local skin reactions, treatment-related adverse events (aes) and serious adverse events (saes). demonstration of effectiveness will be assessed by a significant improvement (reduction) in hyperhidrosis disease severity score (hdss) in subjects treated with the n-sweat patch. secondary and additional endpoints based on complementary clinical instruments, including quality of life measures (qol) and gravimetric sweat production gsp), have been included to further demonstrate performance.

Eligibility criteria:
key inclusion criteria: 1. signed written informed consent 2. at least 22 years old at the time of consent. 3. female or male, who experiences excessive sweating or has been diagnosed with primary axillary focal hyperhidrosis and is in otherwise good general health 4. gsp \>50mg/5min in each axilla 5. reports a score of hdss score of 3 or 4 key exclusion criteria: 1. active skin disease, irritation, or abrasions at either axilla based 2. subject's medical history is indicative of secondary or diffuse hyperhidrosis and/or subject has a diagnosis of secondary or diffuse hyperhidrosis 3. gsp exceeds 300 mg/5min in either axilla

Keywords: excessive axillary sweating primary axillary hyperhidrosis
cryotherapy for neuropathy in children

Conditions: Cancer

Summary: this study aimed to assess the efficacy of cryotherapy in controlling peripheral neuropathy in cancer children

peripheral neuropathy is a serious condition characterized by symmetrical, distal damage to the peripheral nerves that may be caused by several classes of drugs, including chemotherapeutic agents. chemotherapy-induced peripheral neuropathy (cipn) is an adverse effect estimated to occur in up to 40% of patients undergoing chemotherapy, with its incidence increasing in patients being treated with multiple agents. pharmacists play a pivotal role in the prevention and management of cipn by recommending evidence-based pharmacologic and non pharmacologic strategies appropriate for the individual patient.peripheral neuropathy (pn) is a systemic disease characterized by symmetrical, distal damage to the peripheral nerves that negatively impacts patient quality of life (qol). prolonged symptoms associated with pn can cause pain, interfere with functional ability (e.g., dressing, driving, house-work), and disrupt emotional health.

Eligibility criteria:
inclusion criteria: 1. their age will ranging from eight to seventeen years. 2. children participated in this study will from both sexes. 3. children receiving chemotherapy as medical treatment protocol 4. all children have polyneuropathy caused by chemotherapy. exclusion criteria: 1. children with epilepsy. 2. children with blood clotting disorder. 3. children have open wounds / broken skin 4. children with severe cardiac disease 5. uncooperative patients.

Keywords: cancer peripheral neuropathy cryotherapy
evaluation of executive functions in children with cochleovestibular deficit

Conditions: Vestibular Function; Hearing Loss; Cognitive Function; Executive Function

Summary: vestibular system activity supports many functions ranging from gaze stabilization and postural control to high-level cortical functions involving spatial cognition, body perception, verticality perception, orientation, navigation, and spatial memory. few studies have assessed the impact of a vestibular deficit on executive functions taking into account the simultaneous existence of sensorineural deafness in a child population. the brief questionnaire (behavioral rating inventory of executive function) allows a parental assessment of executive functions and is validated from the age of 5. children were recruited from a pediatric population followed in the ear nose and throat (ent) department for audio-vestibular assessment and brief questionnaire was completed by the accompanying parent.

vestibular system activity supports many functions ranging from gaze stabilization and postural control to high-level cortical functions involving spatial cognition, body perception, verticality perception, orientation, navigation, and spatial memory. few studies have assessed the impact of a vestibular deficit on executive functions taking into account the simultaneous existence of sensorineural deafness in a child population. the brief questionnaire (behavioral rating inventory of executive function) allows a parental assessment of executive functions and is validated from the age of 5. children were recruited from a pediatric population followed in the ear nose and throat (ent) department for audio-vestibular assessment and brief questionnaire was completed by the accompanying parent.

Eligibility criteria:
inclusion criteria: * patient aged ≥ 5 years \< 18 years with vestibulopathy confirmed during an ent consultation * affiliated to the social security system * holders of parental authority and patients informed and not opposed to participating in the research * mastery of the french language by patients and their parents exclusion criteria: * refusal to participate * existence of another neurodevelopmental pathology or specific cognitive disorder